| Literature DB >> 32523488 |
Tingshuai Cao1, Yuanchao Cao2, Hongqiang Wang3, Peitao Wang3, Xinsheng Wang2, Haitao Niu2, Cuihua Shao4.
Abstract
Although bisphenol A (BPA) has been associated with impaired spermatogenesis, the mechanisms remain unclear. Tight junction occludin plays important roles in spermatogenesis. The objective of the present study was to explore the effects of BPA exposure in adolescent mice. Male mice were orally treated with low-dose (0.05 mg/kg/d), middle-dose (5.0 mg/kg/d), or high-dose (50 mg/kg/d) BPA in corn oil from postnatal day (PND) 35 to 65. Animals were killed on PND 65 and PND 125. On PND 65, the sperm count, sperm motility, and the expression of occludin showed a dose-related decline. On PND 125, the sperm count, sperm motility, and the expression of occludin were in recovery. However, there remained significant decreases in these parameters in the 50 mg/kg/d group on PND 125 compared with the control. The dose-related effects on the measured parameters and occludin expression suggest an early suppressive or damaging effect on the blood-testis barrier followed by recovery after dosing ceased. At a BPA dose of 50 mg/kg/d, recovery did not occur, suggesting that higher doses of BPA may cause irreversible damage to reproduction in male mice.Entities:
Keywords: bisphenol A; occludin; reproduction; spermatogenesis; spermatozoon
Year: 2020 PMID: 32523488 PMCID: PMC7235676 DOI: 10.1177/1559325820926745
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Spermatozoon Count, Viability Rate, and Motility on PND 65 After Treatment with BPA From PND 35 to 65.a
| Control | 0.05 mg/kg/d | 5 mg/kg/d | 50 mg/kg/d | |
|---|---|---|---|---|
| Density(×106/mL) | 65.29 ± 7.68 | 47.34 ± 3.45b | 34.79 ± 5.01c | 17.36 ± 4.87c |
| Viability rate (%) | 40.41 ± 2.02 | 34.51 ± 2.96d | 28.45 ± 2.16c | 21.42 ± 4.4c |
| Motility level A (%) | 3.42 ± 0.19 | 2.83 ± 0.32d | 2.32 ± 0.35b | 1.26 ± 0.28c |
| Motility level B (%) | 12.49 ± 0.85 | 9.13 ± 1.40d | 6.07 ± 1.26c | 3.05 ± 1.78c |
Abbreviations: BPA, bisphenol A; PND, postnatal day.
a Data are expressed as mean ± SD (n = 8).
b Significantly different from the control, P < .01.
c Significantly different from the control, P < .001.
d Significantly different from the control, *P < .05.
Spermatozoon Count, Viability Rate, and Motility on PND 125 Following Dosing With BPA on PND 35 to 65.a
| Control | 0.05 mg/kg/d | 5 mg/kg/d | 50 mg/kg/d | |
|---|---|---|---|---|
| Density (×106/mL) | 62.73 ± 5.92 | 60.40 ± 4.99 | 60.17 ± 5.11 | 14.84 ± 4.76b |
| Viability rate (%) | 39.54 ± 2.14 | 39.16 ± 1.52 | 38.54 ± 1.63 | 20.01 ± 4.15b |
| Motility level A (%) | 3.23 ± 0.22 | 3.08 ± 0.19 | 2.98 ±.0.16 | 0.91 ± 0.19b |
| Motility level B (%) | 11.54 ± 0.89 | 10.66 ± 1.22 | 10.02 ± 1.17 | 2.16 ± 1.29b |
Abbreviations: BPA, bisphenol A; PND, postnatal day.
a Data are expressed as mean ± SD (n = 8).
b Significantly different from the control, P < .001.
c Significantly different from the control, P < .05.
d Significantly different from the control, P < .01.
Figure 1.Occludin staining (white arrow) decreased with increasing bisphenol A (BPA) dosages compared with that of control on postnatal (PND) 65 (B, C, and D). Occludin staining still decreased in the 50.0 mg/kg/d treatment group compared with that of control on PND 125 (H). On PND 65, occludin staining became light colored or absent in the experimental groups, which was also present in the 50.0 mg/kg/d treatment group on PND 125 (red arrow). Seminiferous tubule cross-sections of testis of mouse (×630). Scale bars = 100 μm. Control (A and E): 0; low dose (B and F): 0.05 mg/kg/d; middle dose (C and G): 5 mg/kg/d; high-dose (D and H): 50 mg/kg/d.
Figure 2.Bisphenol A (BPA) exposure decreased the expression levels of occludin. The protein levels of occludin in whole testis homogenates from postnatal (PND) 65 (A) and from PND 125 (B) were determined by Western blot analysis in response to BPA exposure. GAPDH served as the loading control. Quantified relative protein level between PND 65 and PND 125 (C). *Significant differences between the treatments and the control. #Significant differences between PND 65 and PND 125 in same treatments (*P < .01, # P < .01).